The antihypertensive effect of beta-adrenoceptor blocking drugs has been documented in a number of papers [10--13] and over the last 10 yr beta-receptor blockade has become a more and more frequent primary therapy for hypertension. During this time, a number of different beta-blockers with various degrees of selectivity, potency and intrinsic sympathomimetic effect have come into use. There have also been attempts to reduce the number of daily doses in beta-adrenoceptor blocking therapy while maintaining the antihypertensive effect [5]. Pindolol (Viskén) is a beta-adrenoceptor blocking agent with intrinsic sympathomimetic effect and is characterized by high potency and long duration.